J Hematother Stem Cell Res. 2003 Dec;12(6):701-11
Fassas A, Kazis A.
Department of Hematology, Aristotle University Medical School, George Papanicolaou Hospital, Thessaloniki, Greece
Multiple sclerosis is a relatively common and seriously disabling disease of autoimmune pathogenesis, for which there is currently no cure.
Available therapies include immunomodulating agents and standard-dose immunosuppressants, which may be helpful but are not curative.
Recently, studies in animal models have indicated that control of autoimmune disease can be obtained by high-dose immunosuppression followed by hematopoietic stem cell transplantation (rescue).
Autologous transplants for severe and refractory multiple sclerosis were proposed in 1997 and have been performed ever since in selected patients and in the context of phase I/II trials.
To date, more than 200 patients have been treated worldwide, and similar results were obtained in different centers: high-dose therapy suppresses inflammation in the brain to a degree superior to any other conventional therapy and seems to delay significantly clinical disease progression.
There is, however, a procedure-related mortality risk of 1.5-5%, requiring careful patient selection before transplant.
The treatment should be reserved for patients having high chance of response, i.e., young patients with low disability scores but rapidly progressing disease, having inflammatory rather than neurodegenerative changes in the central nervous system.
The mechanism of action of transplantation is unclear.
The initial concept of immune ablation by high-dose therapy and reconstitution of normal immunity from transplant-derived lymphocyte progenitors has given way to the concept of "resetting" the immune system and of bringing the disease to a lower level of activity.
One could also speculate on a tissue repair effect, given the ability of human hematopoietic stem cells to migrate also into the central nervous system.
The clinical effect of transplantation remains to be demonstrated in a randomized study.
The Autoimmune Disease Working Party of the European Group for Blood and Marrow Transplantation has launched such a trial, comparing transplantation to the currently best available therapy, i.e., mitoxantrone, and in about 5 years we should know whether transplantation offers more than the benefit of a transient immunosuppressive effect.